CXCL5 and neoplasm: Furthermore, RT-qPCR analysis of sorted human tumor-infiltrating macrophages revealed that treatment with rituximab and SE12C3 resulted in significant upregulation of IL1B, TNF, and CXCL5 expression compared with that apparent for the control IgG group, whereas rituximab monotherapy resulted in significant upregulation of PTGS2 (COX2) and CD274 (PD-L1) expression compared with the control IgG or rituximab-SE12C3 groups, respectively (Figure 5F; Supplementary Figure S5B).